Entities

Enterprise Ireland is Ireland’s statutory enterprise-development agency, established under the Industrial Development (Enterprise Ireland) Act 1998. It supports Irish-owned startups and established businesses through investment, enterprise development, research commercialisation, innovation and export-market assistance. It is a public body corporate, not a private venture-capital partnership; its retained database InvestmentFirm type is a legacy classification. Its headquarters are at EastPoint Business Park, The Plaza, Dublin 3, D03 E5R6, and its own legal footer identifies VAT IE9590828H. It is distinct from IDA Ireland, Research Ireland, private Enterprise Equity investment firms and local enterprise bodies. The current published leadership comprises twelve board members and twelve executive-directory entries, representing twenty-three unique people because chief executive Jenny Melia also serves on the board. The government register names her as Jennifer Melia, appointed July14,2025, and chair Jim Woulfe as James Woulfe, appointed February12,2026. Current directory titles take precedence over narrative paragraphs retaining former divisional remits; Mark Christal’s joining year differs between the directory and his January2026 appointment release and is not asserted as settled. Enterprise Ireland provides direct startup investment and supports independently managed seed and venture funds, with portfolio relevance spanning AI, software, advanced manufacturing, climate technology, life sciences, diagnostics and medical devices. Its EUR250M Seed and Venture Capital Scheme2025–2029 is a government capital allocation, not a closed private LP fund. Its Pre-Seed Start Fund uses direct convertible-note support; published per-company limits and tranche conditions are not fund corpus or evidence of any particular issuer ticket. Independently managed recipient funds, agency allocations, cumulative portfolio statistics and company financing events remain distinct. Existing financial IDs and private references are preserved; named portfolio backing alone does not establish stage, date, individual allocation or follow-on participation.

Fabric Ventures is a venture capital firm investing from company inception through growth in the technologies behind the machine economy. It backs robotics, artificial intelligence, financial technology, distributed computing and Web3 infrastructure and applications. Its research-led strategy focuses on how intelligent software, digital assets and decentralized networks can support new businesses and human collaboration. The firm combines investors, founders, operators and engineers with portfolio services, finance and compliance support, ecosystem development and its R[3]sidency accelerator. Fabric developed from the team’s earlier Firestartr investing activity and operates through entities in Luxembourg, London and Dubai.

Samsung Venture Investment Corporation, branded Samsung Ventures, is Samsung’s corporate venture capital manager. It invests globally in companies developing AI, robotics, semiconductors and device technologies, biotechnology and healthcare, energy, security, enterprise software and consumer products. Founded in 1999, it helps portfolio companies connect with Samsung businesses and technology networks. It manages the Samsung Life Science Funds, jointly funded by Samsung C&T, Samsung Biologics and Samsung Bioepis to support innovative biotech companies and strategic partnerships.

Sozo Ventures is the US–Japan venture investment and global-expansion firm founded in2012 by Phil Wickham and Koichiro Nakamura. Its exact adviser is Sozo Ventures LLC, CRD288073 / SEC802-110314, an active exempt reporting adviser rather than a claim of SEC endorsement. Its current site and March24,2026 FormADV connect the RedwoodCity and Tokyo operations. The older sozo.vc domain is the same venture brand, while unrelated Sozo charities, adventure businesses and other homonymous entities are excluded. The firm invests from seed through pre-IPO and helps technology companies develop Japanese/international customers, distribution, executive relationships and expansion strategy. Its published portfolio includes AI/software, robotics and industrial technology alongside digital health and neuroscience: Neurotrack cognitive assessment, Viz.ai clinical workflows, Mercy BioAnalytics diagnostics, Carbon Robotics, Applied Intuition, Saronic, Harmonic, Genspark and other companies. Portfolio inclusion proves a published investment relationship, without automatically specifying current ownership, unexited status, a particular round or cash ticket. A customer introduction or testimonial alone is not allocated investment cash. The current linked directory names27 people across investing, venture partners, business development, finance and operations. Three additional names appear only in the older-domain roster and are retained as historical/source-aged affiliations with current status unconfirmed. Lauren MacDonald appears on the current individual page at its older lauren-gomez path; that own-page continuity is qualified rather than two unrelated identities. Current headings are retained where an older biography describes a prior title. March2026 ADV identifies seven legal fund vehicles, including TrueBridge master/feeder structures. Primary SEC sold snapshots establish USD110M for TrueBridge FundI inMarch2015, USD134M for FundII inFebruary2017 and USD592415615 for FundIII inJanuary2022. These are reported subscriptions/sold snapshots, not invented final-close dates or new2026 raises. The feeder’s2014 headline58M includes25M interests in the feeder and33M directly in the master; it is not an additional58M independent corpus. FundII-S’s initial100M and FundIV’s initial500M were offering targets with zero sold, and current GAV is not fundraising. Later FundIV amendment terms remain inaccessible; confirmed LP activity is described without guessed proceeds. Neurotrack’s actual13.7M March2018 SeriesB primary announcement identifies Sozo as lead; its June2019 USD21M SeriesC includes Sozo as an existing participant. Protected existing investment IDs and private/Goldilocks history are preserved.

Elkstone is an Irish private-market investment and wealth platform established in2011, with venture capital, real estate, private equity, private credit, infrastructure and hedge-fund strategies. Its current own legal footer identifies Elkstone Private Advisors Limited, trading as Elkstone, Elkstone Wealth, Elkstone Private and Elkstone Ventures, as Central Bank of Ireland regulated; CRO primary gazettes identify company528131. A separate real-estate footer identifies Elkstone Capital Partners Limited as unregulated, so group-brand staff and investment relationships are qualified by unit rather than merged into a single legal treasury. Its venture strategy backs tech-enabled, internationally scalable Irish businesses from pre-seed through SeriesA, alongside a direct-investment Venture Club. Relevant public portfolio examples include NeuroBell, ProtexAI, Zerve, LetsGetChecked, LuminateMedical, Manna, SoapBoxLabs and CloudNC. The retained investor identity records the institutional manager platform; an individual fund, SPV or client subscriber is not inferred unless the transaction source establishes it. ISIF confirms Venture FundI closed at EUR100M on May18,2023, with the legal vehicle Elkstone Ireland Ventures I LP identified in NTMA audited accounts. The earlier April2022 launch and final100M close are one fund; ISIF’s15M commitment is not the entire fund. FundII was launched September8,2025, but its150–200M marketing target and100K investor minimum do not prove a closed corpus and remain excluded from amount fields. The current public leadership, venture and real-estate directories jointly name19 people; CEO Joe Bergin replaces historical CEO wording for co-founder Alan Merriman, now Executive Director. Alex Walsh’s differing current directory titles are preserved as source-specific wording. Clientwealth, property-unit counts, portfolio follow-on funding and generic partner logos are not venture fund closes or investee cash. All three existing investment links are preserved pending exact source audit.

Source-attribution audit, October 8, 2026: this imported record is labelled 7wire Ventures and retains Investor 3001 and all original financial IDs. Its healthcare records include issuer-named 7wire investments, while its Kognitos record has primary evidence naming the distinct Prosperity7 Ventures. The verified current 7wire operating manager, legal adviser, public team and fund disclosure are maintained under existing SevenWireVentures / Investor 5695. This legacy mixed-attribution graph is not blanket-merged into that manager. All original amounts, dates, personal/private links and sources remain preserved pending individual issuer-level identity audits; the stored brand/logo does not validate every legacy check.

The Cigna Group Ventures is the strategic corporate venture investment arm of The Cigna Group, operated by Cigna Ventures, LLC, a Delaware wholly owned subsidiary, launched in 2018 to back early and growth-stage health services and technology companies. It invests in whole-person healthcare, including clinical artificial intelligence, behavioral health, precision medicine and digital care, and helps portfolio companies form commercial partnerships across The Cigna Group. Cigna committed USD250 million at launch and an additional USD450 million in 2022; its current strategy page reports USD700 million under management. These figures describe corporate backing, not independently verified external limited-partner fund closings. Evernorth Health Services is a separate Cigna Group business; its acquisition of portfolio company MDLIVE does not make Evernorth the venture arm’s disclosed direct owner.

Early-stage Latin American venture capital investor, distinct from Canary home-security products, Canary Technologies hotel software and Canary workforce relief platform.

Floating Point is an early-stage venture firm based in Boston and New York that backs technology businesses in complex, regulated and capital-intensive industries. It invests in companies combining software and AI with real-world operations, physical assets or financial products, including healthcare, specialty insurance, credit infrastructure, logistics, energy and advanced manufacturing. Founded by former Bridgewater investors and Oscar Health founding-team members Edward Segel and John Loser, it keeps a concentrated portfolio and works closely with founders on underwriting, operations and growth. Its venture partners contribute expertise in product development, healthcare, AI and enterprise sales.

Multi-stage healthcare and life-sciences investment firm funding companies from incubation through private financings, IPOs and public markets. It applies scientific evaluation and data science to precision therapeutics, healthcare delivery and life-sciences infrastructure, including companies using AI and biological data to discover medicines or improve diagnostics. Its investment and operating specialists support company creation, clinical and commercial development, financing and portfolio operations. Foresite Labs is a distinct affiliated company-building platform focused on AI-enabled biomedical innovation.

aMoon is a health technology and life-sciences investment platform operated by aMoon Ventures Y.SH. Ltd., an Israeli manager reporting to the SEC as an exempt reporting adviser (CRD300546). Its Growth strategy invests at later development and commercialization stages, while Velocity supports early-stage biomedical and healthcare technology. Edge invests in public healthcare equities; Alpha is an internal operating and value-creation team, rather than a separate fund. The platform backs computational biology, AI-enabled diagnostics and drug discovery, medical devices, and clinical care businesses including neurodevelopmental care. Its own public roster includes investment and platform staff, venture partners and external advisers; these categories are preserved. Co-founders are physician-investor Yair Schindel and Check Point co-founder Marius Nacht, whom its own site now describes as co-founder and anchor investor. Own biographies differ between2016 and2017 on the founding year, so no single year is asserted. Fund capital disclosures are kept separate from AUM, fund targets and underlying company checks. Existing historical and personally attributed investments are retained under investor2963.

Environmental philanthropic foundation established by Jeremy and Hannelore Grantham. Foundation identity is distinct from Jeremy Grantham’s investment-management firm GMO.

M Ventures is the strategic corporate venture investment business of Merck KGaA, Darmstadt, Germany. Established in2009, it backs biotechnology and technology businesses across healthcare therapeutics, life-science tools, electronics, and frontier technology and sustainability, including neuroscience therapeutics, AI-enabled tools, semiconductors and quantum computing. Its Netherlands legal affiliate is Merck Ventures B.V., registration61910929, Amsterdam; Merck’s2025 consolidated shareholding list reports99.98% ownership. The branded investment profile retains the existing institutional buyer rather than creating duplicate parent and legal-affiliate checks. M Ventures is distinct from unaffiliated US Merck & Co./MSD and its MRL venture business. Its own current directory publishes23 professionals, headed by biotechnology Managing Director Hakan Goker and technology investment head Javier Rodriguez, with Caroline Soulard as CFO. Original current-directory titles control where older individual biographies retain former titles. Merck announced a new EUR600M corporate investment allocation onDecember8,2021 for investment over the following five years; the current website describes that600M allocation. This is corporate sponsor capital capacity, not a demonstrated external-LP fund closing, current AUM or proof that all600M was paid/deployed on the announcement date. No separately verified external-LP fund vehicle or closing is asserted. Earlier employer experience and portfolio board seats are distinguished from current manager employment. Existing investor participations, authentic logo, shared biographies, portraits and prior roles are preserved.

Historical Silicon Valley Bank, the California bank and former wholly owned banking subsidiary of SVB Financial Group, is retained here as a legacy investor identity. It provided banking, venture debt and other financing to technology and life-science companies. The original bank was closed on 10 March 2023; Silicon Valley Bridge Bank was subsequently established, and First-Citizens Bank & Trust Company acquired its loan and deposit business effective 27 March 2023. The successor banking division used the SVB brand and launched First Citizens Innovation Banking for technology and healthcare clients on 6 October 2026. These successor units, SVB Capital, Pinegrove Venture Partners and the separately constituted SVB Innovation Credit Fund VIII are distinct identities. Akili’s 2021 loan contract explicitly names the original bank and Fund VIII as separate lenders. This existing record’s immutable InvestmentFirm classification and historical mixed/protected investment graph are preserved; its old financing relationships have not all been individually recertified or moved to the successor bank. Historical lender tickets are undisclosed unless a specific primary contract proves the amount. No current bank-wide employee roster, current successor logo or independent LP-fund close is attributed to the failed bank.

Video-game and interactive entertainment technology company, creator of Unreal Engine. Corporate investment activity is distinct from being a venture capital fund.

f7 Ventures is an operator-led venture capital firm focused on the future of work and consumer utility. It backs experienced founders building businesses around changing user behavior and advances in AI, and provides operational advice, hiring support and customer introductions. Its public portfolio includes AI companies such as Aircover, Arya Health, Clueso, Fireflies, Lanai and Verix, as well as Corvus Robotics' warehouse inventory automation systems and WorkWhile's machine-learning-enabled labor marketplace. Founding Partners Kelly Graziadei and Joanna Lee Shevelenko are listed as managing members in the firm's February 2026 SEC adviser filing. The firm's public biography also identifies Francisca Gilmore-Yulee as Vice President of Investment and Platform. Other archived operator and fellowship profiles require separate review before treating them as current staff. f7 publicly introduced its first institutional fund at $50 million; its 2026 regulatory filing also identifies a separate Perplexity f7 Fund I LP vehicle without establishing a fundraising size. It participated in Corvus Robotics' $20 million Series A-2 announced August 2026.

Inovo.vc is a Warsaw-based venture capital firm backing pre-seed and seed technology companies founded by entrepreneurs from Central and Eastern Europe, the Baltics and the Balkans, including the diaspora worldwide. Its published initial investment range is €0.5–4 million, with occasional €100,000–250,000 discovery investments and follow-on capital of up to €10 million per company. The firm invests across sectors, including AI, developer tools, enterprise software, healthcare and marketplaces, and can lead or co-lead rounds. Founded in 2014, it has backed more than 70 teams. Fund III totals €107 million; Fund IV targets €90 million according to IFC's 2026 disclosure. EIF and BGK announced a €30 million commitment to a new Inovo fund in August 2026. Inovo operates remotely with offices in Warsaw, Amsterdam and Luxembourg.

SEEDS Capital is the Singapore government-backed early-stage technology co-investment platform operating as SEEDS Capital Pte. Ltd. Its own privacy policy, updated30July2026, explicitly distinguishes that legal corporation from its fund manager, SG Growth Capital Pte. Ltd. SEEDS was established in2001 and previously operated as EnterpriseSingapore’s investment arm; since1April2025 it operates under SG Growth Capital, the combined investment platform of EnterpriseSingapore and the SingaporeEconomicDevelopmentBoard. SEEDS and EDBI retain their own public investment-arm identities. The existing SEEDS profile is retained separately from SG Growth Capital, EnterpriseSingapore, EDBI, SGInnovate and Denmark’s unrelated SeedCapital. SEEDS co-invests with private venture firms and corporate investors into Singapore-based early-stage technology companies with intellectual property and global growth potential. Its published themes span advanced manufacturing and engineering, health and biomedical sciences, agritech and foodtech, maritime technologies, urban sustainability and the digital economy. Publicagency descriptions explicitly include AI, quantum computing and space technologies. It supports technology commercialisation rather than offering ordinary research grants to every listed portfolio company. Co-investment ratios and startup-level caps describe scheme eligibility and leverage, not an individual company check. The current official roster names five investment professionals led by DeputyGeneralManagerJacquelineChia and five investment-panel members chaired by LeeKhengNam. ParentCEOChooHengTong and EnterpriseSingaporeManagingDirectorCindyKhoo appear as panel members; their parent/publicagency titles are not assumed to be SEEDS operating roles. The legal governmentshareholding disclosure also names certain corporate directors, but its reporting date is unspecified and is preserved as a separate governance source rather than silently treated as a complete currentemployment roster. The firm deploys public co-investment capital under StartupSGEquity. Government scheme top-ups, deployment capacity, capital catalysed from partners and aggregate portfolio statistics are not private-LP fund closes. No separately verified closed LPvehicle is asserted here. The own portfolio directory provides company-domain evidence of investment relationships but does not disclose every check date, stage, ticket or whether a holding remains unexited. The2023EngineBiosciences issuer/co-investor announcement explicitly names historicalSEEDSCapital among participants in a USD27millionSeriesAextension; its2023EnterpriseSingapore affiliation is retained alongside currentSGGrowthCapital status. Investment identity audit completed October 7, 2026: two Danish Seed Capital investments and two U.S. XSeed Capital investments were reassigned to their independently verified managers, preserving original financing and participation IDs. Seven Singapore SEEDS Capital relationships remain verified. Undated portfolio affiliations disclose no additional cash raise, stage or individual ticket; Engine Biosciences retains its historical 2023 Enterprise Singapore attribution and current SG Growth Capital ownership qualification.

Public research university. University identity is distinct from any separately managed venture fund or investment arm.

Venture capital firm investing from seed and Series A through growth, with dedicated early-stage and inflection-stage strategies.

Early-stage venture capital firm investing in technology businesses that expand economic opportunity for marginalized communities. It focuses on founders with direct knowledge of underserved markets, primarily at Seed stage, with investments including AI-assisted youth wellbeing company Sonar and cognitive rehabilitation company Moneta Health.

Venture capital firm founded in 2022 by Edoardo E. Ermotti, headquartered in Zug with teams in Zurich and Miami Beach and fund management in Luxembourg. It backs B2B financial technology and software businesses in Europe and the United States from pre-seed through Series A, typically investing USD1–2 million initially. Its portfolio includes financial AI agents, automated accounting and payroll, cybersecurity, encrypted data collaboration and financial infrastructure. It supports founders through operating expertise, recruiting and international expansion. Its first fund closed at USD30 million in April 2024; the firm now invests from its second fund. Fund II remains an ongoing offering: its April 2026 SEC filing reported USD2,442,567 sold toward a USD35,262,450 target, rather than a completed USD35 million close. The current website lists 22 active investments; the USD250 million portfolio fundraising statistic represents capital raised by portfolio companies rather than the firm’s fund size.

La Famiglia is the European and US early-stage technology investment platform behind lafamiglia.vc, backing B2B software, artificial intelligence and industrial transformation. Its industrial-family and entrepreneur network supports technology founders. Its own portfolio includes Groq, Mistral, Applied Intuition, Material Security, Personio, Forto and Vay; portfolio affiliation is distinguished from an individually verified financing stage, ticket and legal subscribing fund. All 17 existing investor participations under retained Investor2861 are preserved. Aizon and SPREAD transaction evidence is handled by their sole issuer owners, without replacing historical La Famiglia checks with General Catalyst or attributing every General Catalyst check to this platform. Legal identity and integration, reviewed October8,2026: the current imprint identifies La Famiglia II GmbH, Berlin HRB257604, tax30/082/79268, c/o General Catalyst at Schönhauser Allee8. Current published managing directors are Dr. Jeannette zu Fürstenberg and Marius Groke. The imprint explicitly reports an October2024 change of fund manager from La Famiglia GmbH to La Famiglia II GmbH. These are distinct underlying legal managers; this does not prove a company rename, merger or transfer of every historical financial obligation. Older terms still name La Famiglia GmbH HRB206828B and Jeannette/Judith Dada, and are qualified as superseded disclosures. The FundIII LEI391200LOFSQ7AM1ELY39 belongs to the fund, not the manager. General Catalyst announced joining forces October16,2023; Jeannette’s own November13,2025 account describes La Famiglia as the nucleus of GC Famiglia Europe. The historical fund platform and current legal management are preserved without creating a duplicate GC parent or cloning its worldwide team. Public team scope: current legal directors Jeannette and Marius are recorded, plus source-confirmed historical founding partner Robert Lacher, historical general partner/co-leader Judith Dada and historical team member Saket Kumar. Visionaries’ January2026 retrospective says Robert led the first fund through2025 and Judith joined in2017. Its June25,2026 announcement says Judith becomes Langdock Co-CEO and continues as a Senior Partner in a future Visionaries fund generation, stepping down from the current generation’s managing-director role; she is not presented as current La Famiglia operating staff. GC’s January2026 retrospective identifies Saket’s historical La Famiglia tenure before Vitt and Prime Meridian. The linked old La Famiglia /team page returns404; a complete historical roster and authentic portraits for Marius and Saket remain research gaps. Authentic named Robert and Judith portraits are taken from their own current Visionaries directory; Jeannette’s existing authentic portrait is preserved. No stock or portfolio-founder images substitute for manager staff. Actual fund closes: transaction counsel YPOG reports SeedI EUR35M closed2017, SeedII EUR60M closed2019, SeedIII EUR165M closed endFebruary2023 and GrowthI EUR90M closedDecember2022. The two latest funds were jointly announced March8,2023, aggregate EUR255M; this aggregate is not an additional fifth fund. FundIII’s exact legal name and LEI come from the own imprint, FundII’s legal name is confirmed by EIF. Earlier exact announcement/closing days are unknown. Subsequent GC global programmes, AUM, investment targets, portfolio valuations and LP investment affiliations are not booked as La Famiglia cash closes. Four actual fund records are source-qualified; individual underlying-company fund allocations remain unasserted unless transaction evidence proves them.

An Amsterdam-based venture firm, formerly Dutch Founders Fund, that invests at pre-seed and seed in vertical AI, marketplaces, recommerce and software for industries that still rely heavily on manual operations.

Headline provides venture and growth capital to technology companies through regional early-stage funds in the US, Europe, Asia and Latin America and a global growth strategy. It backs companies in AI, software, infrastructure, consumer products and financial technology.

Micron Ventures is the corporate venture investment arm of memory and storage semiconductor manufacturer Micron Technology. It makes early-stage equity investments in deep technology and AI startups and supports founders with semiconductor expertise, market and ecosystem knowledge and enterprise product development. Its investments span AI computing, chip interconnects, data infrastructure, industrial automation, materials, healthcare and sustainability. The Paradigm Fund expands its AI strategy across model architectures, compute and networking infrastructure, enterprise applications and physical AI such as robotics.

Future Planet Capital is an impact-led venture investment group backing companies that commercialise research from universities and major innovation ecosystems. It invests across health, climate, education, security and sustainable growth, combining global growth-stage strategies with UK seed and regional investment programmes. Its global strategies include Future Planet Fund, Challenge Response and the Blue Ocean mandate; its UK national work includes the evergreen UK Innovation & Science Seed Fund, while its regional team backs West Midlands businesses. The regulated manager Future Planet Capital (Ventures) Limited (company 02500898, FCA FRN 148549) manages UKI2S and was formerly Midven Limited. The group and its individual mandates are distinct: group assets under management, public-sector programme totals and portfolio-company financing are not individual fund corpus. The current official team directory publishes30 investment, operating and regional/national/global team members, four external advisory-board members and three investment-governance-board members. Sixteen existing additional roles are retained in their published standalone staff or UKI2S adviser scope; UKI2S external advisers are not asserted to be permanent Future Planet group staff. The profile preserves all53 existing people and role IDs, current-name homonym distinctions and meaningful biographies and outside affiliations. The original authentic logo and three already published personal portraits remain unchanged. Genuine original publisher photographs fill the previously missing portraits where publicly accessible; four remaining image gaps are documented rather than substituted with generic images. The own legal disclaimer identifies Future Planet Capital (Ventures) Limited, UK company02500898 and FCA firm148549, as the regulated fund manager for professional clients. The group umbrella, this regulated UK manager, specific fund vehicles and government programme mandates are distinct identities. UKI2S is evergreen and recycles proceeds. Its June10,2026 announcement reports an additional GBP33.25M of public-sector support and total available capacity of GBP150M. That total capacity is retained in description and evidence rather than a structured new private-LP closing amount. The British Co-Investment Fund’s launch announcement remains separately preserved, with an unverified proposed fundraising size not booked as cash. The current funds directory additionally identifies Future Planet Fund I, BIF Opportunities Fund and RT Capital Funds I and II. Exact closed subscription amounts and days are not supplied for these individual vehicles. The RT pair has GBP38M aggregate commitments according to the current own website; that combined figure is not assigned to both funds, split by guess or represented as paid-in cash. Historical primary Inivata transaction documentation separately names RT CAPITAL FUND I LP with general partner RT CAPITAL MANAGEMENT, and RT CAPITAL FUND II LP with general partner RT CAPITAL MANAGEMENT II. A historical Cayman address and statutory signing director in that document do not automatically establish the full current staff or domicile of the group. Future Planet’s own November22,2021 report confirms completed acquisition of RT Capital alongside Milltrust Agricultural Investments and Midven. RT is an acquired science-investment platform associated with the Oxford/Cambridge university ecosystem, not an alias for unrelated Australian wealth managers, Brazilian wealth businesses, Canadian institutional managers or newly incorporated HongKong entities. Current RT-fund contacts are Ed Phillips and Alex Shadbolt; group advisory members are not automatically managers of every vehicle. However Oxford VR’s September20,2018 issuer financing announcement supplies only the literal name RT Capital, with no legal entity, exact subscribing fund or manager domain. That particular historic legal bridge remains unresolved: no new RT investor shell or retrospective2018 Future Planet participation is created. Existing group checks are preserved and new portfolio cards are research leads, not inferred priced transactions. Challenge Response describes thematic investment baskets and Blue Ocean a Monaco-linked mandate. MEIF and West Midlands co-investment figures are programme allocations or available fund capacities in the reviewed source. Corporate AUM, government envelopes, available programme capacity, aggregate commitments and portfolio-company total raised figures are not added as individual closed fund cash.

European venture capital firm backing companies from seed through Series B across sectors. It combines investment with operating support, talent connections and go-to-market help for European founders pursuing international growth. Its portfolio includes AI infrastructure, cybersecurity, materials technology, mental-health platforms and AI-enabled life sciences. It operates from Paris and London under Singular Capital Partners.

Martin Ventures is the Nashville healthcare investment and company-building business of Martin Ventures, LLC, founded in 2009 by healthcare operator Charlie Martin (Charles N. Martin Jr.). Its own public strategy explicitly states that it invests its own capital and does not have an investment fund. The team backs and co-creates healthcare services and technology businesses, including digital health, value-based care, artificial intelligence and data science. It supports portfolio companies through operating expertise, recruiting, introductions, finance and clinical advice. Its current public directory names nine people, including three investment-committee members. Portfolio examples include neurodegenerative-disease care company Synapticure, chronic-pain care company Override and disability-focused StationMD, alongside health-data and AI software companies. Published enterprise value and initial-check criteria are portfolio operating metrics or investment targets, not assets under management, closed fund capital or proven individual investment amounts. The legal LLC is corroborated by its primary SEC-filed administrative-services agreement; no unrelated Lockheed Martin or similarly named medical provider is merged.

Optum Ventures is a healthcare technology investment platform founded2017 in partnership with UnitedHealth Group. It invests from seed through growth equity in care delivery, enterprise software, enabling infrastructure and healthcare financial technology, and helps portfolio businesses develop commercial relationships across the health ecosystem. Its official portfolio includes healthcare AI operating systems and scribes, clinical and workflow agents, neuroscience care and brain-imaging software, AI-enabled hearing aids, behavioral-health data and virtual rehabilitation. Examples include AmbienceHealthcare, Synapticure, Holmusk, icometrix, Fortell and XRHealth. These portfolio descriptions establish investment relevance, not independent clinical approval or undisclosed cash allocations. Legal identity reviewed October8,2026: existing OptumVentures/Investor2773 is retained, with all prior financial IDs and company relationships preserved. The September10,2026 SEC FormADV identifies Optum Venture Management,LLC d/b/a OptumVentures, CRD290116, SEC802-111924, an exempt reporting adviser, not an asserted SEC-registered adviser. The own privacy policy uses the singular Venture legalname; the terms page uses plural Ventures Management,LLC, a drafting discrepancy qualified against the current statutory adviser filing. Optum Ventures Global Management UK Limited is a distinct related UK manager and appointed representative of LanghamHallFundManagementLLP according to the official legal footer. These capacities are distinct from corporate Optum/UnitedHealthGroup and from investment partnerships/GPs; no parent or fund-as-manager duplicate is created. UHG’s2018proxy describes its99% LP interest in historical OptumVenturePartnersLP and24MUSD contributed throughDecember31,2017, while the management company and GP were Renfro-owned. That dated relationship is not represented as present-day wholly owned corporate-manager status or current allocation to every portfolio check. The full current own website directory publishes28individuals across investment, global, executive-in-residence, finance/legal, portfolio operations, marketing and administrative roles. Twenty-five genuine original individuallyassociated photographs have been downloaded and visually inspected. JulietDomb,MorganNoonan and ElizabethLuke own assets are generic firm-mark placeholders, explicitly excluded as portraits. VijayBarathan’s existing person and externalXRHealth role are reused and preserved. KateLeonard the Optum general counsel is separately qualified from the existing LuminateNY digital-marketing namesake. Website titles remain exact: JulieJoyce is headed SeniorExecutiveAssistant while biography says ExecutiveAssistant; TaylorTrepagnier heading InvestmentTeamAssistant versus biography AdministrativeAssistant. Published legal/funddirectors and formerOptumexecutives are not silently cloned into current venture staff. Capital and funds: the current official about page reports over2BUSD AUM across six funds and over75portfolio companies, while some own team bios refer to65+companies. These are source-dated operational counts and asset-management measures, not cash raised. The newer September10,2026 ADV separately lists seven exact Delaware private partnerships: OptumVenturePartnersLP,II,III,IV,V and OptumVentureGlobalPartnersLP/II. Every legalvehicle is recorded distinctly with exact privatefundID/GP and amount/dateNULL because current gross asset values, minimum commitments and reported AUM are not actual closed-subscription cash. The historical250MUSD launch headline is not booked as a newly verified LP final close; UHG’s actual24Mcontributed-to-date2017 amount is source-qualified historical partial capital, not totalfundsize. No duplicate parent capital check, budget-as-fundclose, inferred portfolio ticket or unproved fund allocation is introduced. Existing investments are preserved and reviewed alongside the official portfolio. Synapticure’s actual25MUSD SeriesA announcedNovember19,2024 names OptumVentures as an existing participant; retained round18022/IP38019 is reused with ticketNULL, without a second cash event or a personalpartner check. The broad official portfolio is saved with exactdomains/entryyears/stages for full-company follow-up. An undated portfolio card or generic Growth/Early label does not establish a specific financing stage, check amount or cash day, and sparse missing issuers are queued for full enrichment rather than created as bare shells.

RA Capital Management is a multi-stage investment manager combining scientific research, venture creation, private financing and public-market healthcare investing. Its current website describes founding, funding and scaling companies across healthcare and planetary health, with a history dating to2004. The healthcare strategy covers therapeutics, devices, diagnostics and research tools, including neuroscience and neurodegenerative diseases. TechAtlas develops scientific competitive landscapes and diligence; Raven is the internal healthcare company-building incubator and Blackbird supports clinical development. These internal teams and services are distinguished from independent external fund managers. The exact current legal adviser is RA Capital Management LP, CRD160174, SEC801-73980 and CIK1346824, independently confirmed by its March31,2026 original FormADV and ownsite footer. Historical issuer releases use the predecessor LLC name; current LP legal identity is preserved under the existing manager record. The firm publishes offices in Boston, SanFrancisco and NewYork. The current own directory has277 named profiles across Healthcare, PlanetaryHealth, Operations and Raven, including employees, partners and explicitly labelled external advisers. Every role retains its published scope; an adviser is not automatically an employee or generalpartner. Actual source-proven first/final fund closes include RA Capital Nexus FundII USD461M announcedOctober21,2020, Nexus FundIII USD880M announcedOctober6,2021 and the inaugural PlanetaryHealth Fund USD120M announcedJuly22,2025. The July15,2019 inaugural Nexus close is described as just overUSD300M, so an unverified exact cash amount is not invented. Current master and international feeder vehicles are individually identified in the adviser filing without doublecounting mastercapital. The current filing repeats a privatefund identifier across NexusInternationalIII/IV; their distinct legalnames are preserved with the identifier ambiguity explicit. The website’s USD14.4B assets-under-management figure atDecember31,2025 and USD650M-plus2025privatefinancing deployment are management/deployment statistics, not new fund raises. Portfolio acquisitions such as AbbVie’sUSD1.4B acquisition ofAliada are transaction consideration, not RA manager fundraising. Specific historical subscribing funds and personal investor allocations remain unknown unless primary company sources independently identify them. The retained SynapticureNovember2024USD25MSeriesA participation is preserved; the company-owner source enrichment doesnot create another check.

OpenAI Startup Fund is a venture investment manager backing early-stage companies applying AI to healthcare, legal services, education, energy, infrastructure, science and productivity. It combines capital with expertise in investing, machine learning, engineering, talent and operations. Its Converge program offers investments and access to AI practitioners for founders building transformative products; participants are not required to use OpenAI’s APIs. Microsoft and other OpenAI partners are investors, while OpenAI itself is not an investor in the manager’s originally described fund.

Dimension is a multistage, research-oriented venture investment firm partnering with companies across the frontiers of science and compute. Its published strategy spans artificial intelligence, computing infrastructure, biotechnology and automated laboratories. Relevant verified exposure includes Automata laboratory robotics/software and AI-ready wet labs; Dimension’s own July2026 announcements describe co-leading Chai Discovery’s biological AI Series C, and its research examines training data for biological foundation models. Its published Research team includes Bauer LeSavage, whose primary Stanford biography documents human neural stem-cell engineering research. These affiliations establish AI/deep-technology and neuroscience relevance without asserting independent clinical efficacy. The exact adviser is Dimension Management, L.P., CRD322490, distinguished from unrelated Dimension funds, Six Dimensions, Japanese Dimension and software/waste-management companies. The March24,2026 legal filing names founders/managing partners Zavain Dar, Adam Lander Goulburn and Nan Li, and two actual private fund vehicles: Dimension Capital I,L.P. and Dimension Capital II,L.P.; both have separately named GP partnerships. The current website publishes five investment, three research and five operations members. An additional July29,2026 own announcement confirms former Recursion CEO Chris Gibson joining; the firm-reposted direct interview qualifies his operating-partner role separately from the 13-person homepage. Recursion’s own current biography dates Zavain’s Dimension founder role to March2022, while public launch was January2023. Primary Automata’s2023 announcement describes the first USD350million fund; its exact closing day remains unknown. Dimension’s ownDecember9,2024 announcement and December16 founder interview confirm the USD500million second fund, and its ownJuly21,2026 post announces the USD800million Dimension III fund. These are separate pooled vehicles, not AUM or targets; III is a current public brand fund, and its exact legal GP/private-fund identifier was not independently secured from the earlier March2026 ADV. Public fund letters remain linked, but the embedded reader text could not be independently extracted. Seven authenticated portraits, including existing shared Nan Li and Darsh Patel photos, are secured; seven remaining public-team portraits are unavailable rather than replaced with generic avatars. Existing investment IDs, personal investor identities, Automata directorships and unrelated historic affiliations are preserved.

EDBI is a Singapore-based global technology investor established in 1991 as EDB Investments. It supports high-growth companies developing capabilities in Singapore and across Asia through direct investments, fund commitments and portfolio-growth partnerships. Its current sectors include Digital Economy, Healthcare, Green and Bio Economy, Next Generation Hardware, Early-stage and Fund-of-Funds. EDBI and SEEDS Capital came together under SG Growth Capital, the government investment platform of the Economic Development Board and Enterprise Singapore, effective 1 April 2025. EDBI continues as a distinct investment arm led by Paul Ng; its historical transactions retain EDBI attribution rather than being reassigned to the parent or SEEDS. Its portfolio spans AI drug discovery, neuroscience, digital therapeutics, semiconductor and quantum technologies. The published team contains 30 current named professionals. The former Bio*One Capital biomedical platform and jointly administered Special Situation Fund for Startups are separately qualified; scheme budgets, co-investee fundraising totals and commitments to external fund managers are not claimed as EDBI private-fund closes.

Xfund is a US early-stage venture investment manager supporting multidisciplinary founders and research-based technology through networks around Harvard, MIT and Stanford. Its published investment interests include artificial intelligence, enterprise software, robotics and autonomy, computational healthcare, neurotechnology and advanced research commercialization. Its public team includes five investment professionals, sixteen faculty/advisory affiliations and fourteen university/community fellows; the latter two categories are not represented as employees, investment partners or personal investors. The exact SEC-reporting legal manager is Xfund Management Company, LLC, CRD176521 and exempt-reporting file802-88200. The latest reviewed annual amendment is13March2026, with a Palo Alto principal office. Exempt reporting does not establish SEC registration. Experiment Fund was its2012 predecessor; the Xfund partnership was co-founded in2014 by Patrick Chung and Hugo Van Vuuren and is now publicly managed by Patrick Chung and Brandon Farwell. Hugo is historical, not on the current published investment team. The manager is distinct from cryptocurrency xFUND/Unification, Japanese Xfund and Jamaican real-estate XFund. University affiliations do not establish university control or individual university LP commitments. Primary SEC offering records identify Xfund2,L.P. with USD100million fund interests sold by11December2014 and Xfund3,L.P. with USD120million sold by3September2020. Xfund’s own3September2020 announcement corroborates the oversubscribed USD120million third fund. Those totals are not cash drawn from every LP. XFund Opportunities1,L.P. reported USD50million offered and zero sold on11May2022; this is an offering snapshot, not a verified USD50million close or evidence that it remains unraised today. The secondary USD270million headline improperly sums an unraised offering and is not imported as closed capital. The current directory names Patrick Chung, Brandon Farwell, Tuan Ho, Prat Mallick and Jadyn Bryden. The directory lists Jadyn as Venture Partner while her undated detail biography still says Vice President; the current directory controls the imported role. External faculty/adviser titles are published context and may be aged: Jim Wilkinson’s interim Oxford Science Enterprises CEO caption is historical, and Companies House records the relevant former directorship ending31March2026. Individual career investments, including prior NEA/DFJ activity, are not automatically Xfund investments. Team biographies include prior-employer investments and personal angel activity, which are not automatically Xfund checks. The current portfolio page publishes company cards but does not establish manager cash amounts, current holding status, subscribing fund or financing dates for every logo. Existing institutional participations and all private/personal provenance remain preserved.

Cherubic Ventures is a global venture capital firm investing at pre-seed and seed, often before companies reach product-market fit. Led by founder and solo general partner Matt Cheng, it supports founders from their earliest stages through later growth. Its sixth fund backs AI-native infrastructure, developer tools, enterprise software, healthcare, physical AI and robotics. The firm also has longstanding investments in space technology, digital health, logistics and financial software.

Venture capital firm dedicated to consumer and prosumer technology, investing across stages with a data-informed approach.

Luminous Ventures is the legacy London-based early-stage deep-technology venture fund platform focused on applications in healthcare and life sciences, investing at Seed and Series A across Europe and North America. Its current own website explicitly says the fund is fully deployed and is not making new investments. A December2018 firm-issued Business Wire announcement described a USD30 million family-backed fund spun out of White Cloud Capital, with partners Isabel Fox and Lomax Ward and a portfolio including Synthace, Hadean, BioBeats and FaceSoft. That announced corpus is not assigned an invented final-close day or statutory limited-partnership suffix. The historical management company Luminous Ventures Limited, company11416023, was renamed Outsized Ventures Limited on May28,2021; the registry shows it was incorporated June14,2018 and began using the Luminous name August1,2018. The legacy Luminous website retains FCA reference927589, also used by Outsized. The separately retained Outsized database record, new funds and current team are not merged or attributed wholesale to this deployed legacy fund. An unrelated UK company09549872, luminousvc.com namesake and Luminous Computing are excluded. Historical team affiliations are qualified; the current Luminous site does not publish a live investment team.

Rock Health Capital is the early-stage digital-health venture investment business associated with the broader Rock Health platform. It invests at pre-seed, seed and SeriesA in technology addressing healthcare delivery, clinical workflows, patient access, research and health outcomes. Its own portfolio includes cognitive-health technology Neurotrack, neural/assistive Lift Labs, AI-enabled clinical tools and analytics, laboratory infrastructure, mental-health care and digital medicine. Investment backing is distinguished from enterprise consulting clients, nonprofit fellows and event participants. Synapticure’s19November2024 issuer release separately identifies Rock Health Capital as an existing investor participating in its USD25M SeriesA for neurodegenerative-disease virtual care. The current legal investment adviser is Examen Management LLC, trading as Rock Health Capital, CRD322958 and SEC exempt-reporting-adviser file802-129744. Its26March2026 FormADV names William Oliver Evans as managing member and reports two Delaware private vehicles: Rock Health Capital FundI, L.P., with Rock Health Capital GPI LLC as general partner, and Rock Health Seed FundII LLC, managed by Examen Management LLC. This retained institutional brand preserves historical Rock Health investments; it does not pretend every older subscription was made by the current adviser or the same fund. The platform’s strategy-consulting business Rock Health Advisory and the separate RockHealth.org nonprofit are related organisations with different mandates, not interchangeable venture buyers. The current capital directory publishes founder/general partner Bill Evans, principal Sean Day and advisers Hylton Kalvaria, Keith W Anderson and Monique Smith. Adviser affiliations do not imply executive employment, fund ownership or personal portfolio checks. The directory’s playful pet entries are excluded from person records. Bill Evans’s own biography and SEC legal identity describe the same healthcare investor; the unrelated Dexory sales director already named Bill Evans is preserved separately. A23December2014 SEC filing for Rock Health Seed FundII LLC reports USD4.9M sold to ten investors, first sale22December2014, with no remaining offering amount. This is an actual filed subscription snapshot, not a newly inferred2026 fund close. Capital FundI’s May2022 notice offered USD50M with zero sold; the50M target is not entered as raised capital. Evans’s25July2022 primary account confirms a first close without disclosing its amount or exact closing day. Official submissions list a14July2023 amendment whose full terms were inaccessible; current ADV gross asset values are not treated as historical proceeds or final commitments.

SignalFire is a venture capital firm backing companies from pre-seed through Series B, with a focus on enterprise AI, cybersecurity, healthcare and pharmaceutical technology, developer tools and fintech. It uses its Beacon AI platform for investment research and recruiting, alongside support for hiring, company operations and go-to-market strategy.

Eurazeo is a European private-markets investment group providing private-equity, private-debt and real-asset capital to companies at different stages of development. Its strategies include buyouts, technology growth, healthcare, venture capital, secondaries, direct lending, asset-based finance, infrastructure and real estate. The Growth team backs European technology companies scaling internationally, including businesses using AI to change enterprise software and services, and supplies investment and operating support. Eurazeo Global Investor (EGI), AMF registration GP97-117, is a regulated French alternative investment fund manager within the group. Official EIF fund-partner records identify EGI as manager of Eurazeo Growth Fund IV S.L.P.; Eurazeo Growth is a business strategy rather than a separate invented management company. Other group strategies may use different regulated affiliates, including Luxembourg, North American, infrastructure and Kurma entities.

Haystack is the San Francisco early-stage venture capital firm founded by Semil Shah in2013, operating as Haystack Management Company LLC as identified in its founder’s own copyright notice. It invests in software and technology companies at pre-seed and seed, typically providing USD1M–3M initial investments and leading or participating. Its own portfolio spans artificial intelligence, developer infrastructure, autonomous systems, advanced manufacturing and aerospace as well as consumer and enterprise software. Current public team sources name founding partner Semil Shah and principal Divya Dhulipala; the firm directory still names Aashay Sanghvi as partner, while his own current personal site explicitly describes that role as previous, a discrepancy preserved as a qualified historical affiliation. Haystack’s founder confirmed inApril2026 that it had raised an USD85M eighth core fund and USD25M NeedlesIII companion fund earlier that year; those are fundraise amounts rather than company tickets, with exact close days undisclosed. Earlier primary disclosures confirm the first fund’s actual970,000USD corpus and VII fundraising in spring2023, without extrapolating missing fund targets, AUM or drawdowns. This manager is distinct from namesake Haystack Analytics, recruiting, observatory and oncology companies. Existing investor2633 and all protected historical portfolio and personal-attribution references are preserved.

Science-driven venture capital firm founded in 2018 by Michael P. Rubin and Sharon Kedar, with offices in Bethesda, Cambridge and San Francisco. Northpond invests in biotechnology, diagnostics, digital health, research tools and emerging technologies, including AI-enabled drug discovery, precision medicine and neurotherapeutics. Its portfolio includes Transition Bio, CAMP4 Therapeutics, Octave Bioscience, Scipher Medicine, Vizgen and Faro Health. Northpond Labs is a research and development affiliate that works with academic institutions to help translate scientific discoveries into new ventures. The firm publishes a thirty-person team and a selected portfolio spanning active, public and acquired businesses. Its named private investment vehicles include Northpond Ventures, LP and Funds II and III; firm-wide committed capital is distinct from any one fund size.

Primetime Partners is a New York investment platform focused on aging, longevity and services for older adults. Its own current site describes early-stage investing and incubation across healthcare, financial services and consumer products, with operational, distribution and adviser support. Co-founders Abby Miller Levy and Alan Patricof lead the published four-person staff roster; ten separately published external advisers are recorded as advisers, with outside-employer descriptors qualified rather than asserted as current employment. The March17,2026 primary FormADV identifies Primetime Partners Management Company, LLC, CRD310695/SEC802-119592, as the exempt reporting adviser and names one current legal FundI vehicle. Regulatory gross asset value is not raised cash. A June2026 firsthand founder interview reports historical FundI fundraising of50M and a55M FundII close in2025 followed by returning its commitments to LPs, with the platform remaining active through personal capital/SPVs and company creation. Exact FundII legal vehicle and final cash/return dates remain unavailable, so reported historical amounts are not treated as present available capital. Isaac Health's own2024 and2025 announcements name Primetime as an investor; precise tickets and legal subscribing vehicles are unpublished.

Venture capital platform co-investing in institutional-led Seed and Series A financings through six regional funds. Its service-provider investor network helps portfolio businesses connect with customers, financing and operating expertise; its investments include radiology AI company Quantivly.

APEX Ventures is a Vienna-based venture capital manager investing in European deep-tech companies from seed through Series A. It backs scientific and engineering businesses in artificial intelligence, robotics and autonomous systems, next-generation computing, medical technology, energy transition and space. Its medical portfolio includes neurological biomarkers, stroke diagnostics and surgical robotics. It manages dedicated deep-tech and digital-health vehicles and partners with Amadeus Capital Partners on the Amadeus APEX Technology Fund.

Early-stage venture firm backing founders building category-defining consumer businesses and platforms.

Hercules Capital, Inc. (NYSE: HTGC) is a publicly traded, internally managed business development company and specialty venture lender founded in December2003. It provides senior secured loans and related equity and warrant investments to venture-backed technology and life-sciences companies. Its current published team comprises 45 executives and lending/operating professionals; its board includes CEO/CIO Scott Bluestein and seven additional directors. Seth Meyer became president and Andrew Olson CFO effective May18,2026. Relevant borrowers and historical portfolio companies include Alamar Biosciences, neuroscience and psychiatric drug developers, surgical robotics and AI software businesses. Principal offices are in San Mateo, California. The company also owns Hercules Adviser LLC, a separately registered investment adviser managing external institutional private-credit vehicles; those vehicle identities and amounts are qualified separately. Legally the parent is a public BDC and specialty finance corporation. Loan commitments, credit-facility limits, portfolio principal and assets under management are not additional cash fundraising. The October5,2026 priced USD400million notes announcement is pending closing as of this audit and is not treated as completed financing. Completed financing includes a USD78million gross IPO in June2005 and recent closed unsecured note issues of USD287.5million in March2025, USD350million in June2025, USD300million in February2026 and USD325million in July2026.

M12 is Microsoft’s corporate venture capital arm, founded in 2016 as Microsoft Ventures and renamed M12 in 2018. It invests in early-stage software businesses and helps portfolio companies connect with Microsoft technology, customers and distribution. Its current focus areas are AI applications, security for AI, AI cloud infrastructure, AI data operations and models, and deep technology and systems. Corporate Vice President and Global Head Michelle Gonzalez leads its published investment, operations and portfolio-development team. Its public portfolio includes AI and developer infrastructure companies such as Arcee AI, Arize AI, d-Matrix and DatologyAI. M12 partners with GitHub on a named open-source seed-investment program launched in November2022. The program’s announced USD10M allocation is corporate funding, not a verified external LP fund close. Microsoft’s direct investments in OpenAI and its Climate Innovation Fund’s Fortera investment are distinct from M12’s venture investing.

NVentures is NVIDIA’s venture-investment unit, led by Mohamed (Sid) Siddeek. It invests in companies building AI, digital biology, healthcare, robotics, infrastructure, industrial technology and other computing-enabled businesses, and supports portfolio companies with technical and ecosystem expertise. Its current NVIDIA-hosted portfolio directory lists96 companies, including Luma Labs, Abridge, Iambic, Genesis, Relation and Waabi. NVIDIA distinguishes NVentures from its corporate-development investment group and from the Inception startup-support programme. SEC subsidiary disclosures identify NVentures LLC as a wholly owned US subsidiary; however, a platform relationship does not establish that LLC as the subscriber in every transaction: an April2026 Iambic agreement names NVIDIA Corporation and Siddeek as NVIDIA VP and NVentures president/managing director. This profile retains the venture-unit investment graph separately from existing NVIDIA corporate records. The image is the genuine NVIDIA brand mark displayed on the unit’s own page, not an invented distinct NVentures logo. Publicly documented team affiliations include Siddeek, John Wesley, Vega Shah, Christina Buchanan and Chase Overlie; the latter’s formal title and portrait remain unverified. No external LP fund close or finite fund commitment is publicly established here. Existing39 investment links are preserved pending source-by-source attribution review.

QED Investors is an Alexandria, Virginia-based venture-capital manager founded in2007 by former Capital One operators Nigel Morris and Frank Rotman; the firm’s own historical timeline also credits co-founder Caribou Honig. Its SEC FormADV identifies QED Investors LLC, CRD284908, as an exempt reporting adviser with file802-122363, not a claim of full SEC investment-adviser registration. The firm focuses on financial technology globally, including AI-supported credit analytics, payments, banking infrastructure, fraud prevention, enterprise software and healthcare financial integrity. It supports early-stage and growth companies through investment, operating advice and its platform team. Its source-confirmed healthcare AI portfolio includes Codoxo, previously FraudScope. The current public directory names34 people in investment, finance, platform and administrative roles, with emeritus partners distinguished from active investing titles; a canine mascot is not entered as a Person. Matt and Matthew Risley are explicitly the same individual in the own named biography and currently a Partner Emeritus; historical investee board roles are recorded separately. Primary closed-capital disclosures include FundVI350M, early-stage FundVII550M and GrowthI500M, FundVIII650M and GrowthII275M, plus the12M Fontes LatinAmerica seed strategy. The combined1.05B and925M announcements are split into their constituent vehicles, not duplicated as extra aggregate funds. The own timeline confirms FundV closed in2018, but its amount and exact closing day remain unverified here. Reported AUM, targets, average check sizes and historical fund totals are not substituted for cash commitments or individual portfolio tickets. All34 prior investment records are preserved, with further exact issuer/subscriber review queued rather than reassigned.

Sands Capital is an independent, staff-owned global growth investor founded in 1992, with public-equity, venture and private-growth strategies. The umbrella platform combines separately registered advisers Sands Capital Management, LLC and Sands Capital Alternatives, LLC (CRD155517/SEC801-72115), the latter previously operating as Sands Capital Ventures, LLC. Private strategies include Global Venture, Global Innovation and Life Sciences Pulse, backing enterprise software, AI infrastructure and biotechnology, including proteomics and neuroscience. The published firmwide directory names 174 current people across investment, research, client relations, operations and support functions; it does not imply all staff are employed by the alternatives adviser. Historical life-sciences executive Ian W. Ratcliffe is memorial-qualified, not a current employee. The firm reports USD47 billion in client assets as of September30,2026, a management metric rather than cash raised by a fund. Distinct legal fund vehicles and verified closed commitments are qualified separately; parallel or feeder totals are not counted again. Existing historical investment checks, personal attributions and protected references are retained.

Silent Ventures is an early-stage venture capital firm investing primarily at concept, pre-seed and seed in aerospace, defence, national security and related deep technology. Founded and managed by Jackson Moses, it backs companies building autonomous systems, advanced manufacturing, space infrastructure, energy technology and software for defence applications. The firm publishes a portfolio of first investments in early-stage companies and separately labels its founder’s prior investments; Silent Capital is a separate private syndicate.

Wildcat Capital Management, LLC is a New York investment adviser founded in 2011, initially as the single-family office for David Bonderman. Its current legal disclosures identify Wildcat as an independent adviser and expressly state that it is not owned, controlled or managed by Bonderman. The firm makes flexible, partnership-oriented investments across venture, growth equity, buyouts and real estate, providing capital and strategic support to management teams. It considers majority and minority investments, primary growth capital and secondary transactions, with a flexible investment horizon. Its technology and neuroscience portfolio includes NeuroVision Imaging, which develops biomarkers for neurodegenerative disease, and Mednition, which develops clinical artificial-intelligence software; additional technology holdings include Glia, Skillz, Robinhood, Coupang and aerospace company Astra. The own-site portfolio distinguishes active and realized investments and records initial investment years without disclosing individual cheque amounts. Its current team is led by founder Len Potter, legally Leonard A. Potter, as CEO and chief investment officer, with Drew Tarlow leading private investments and George Stone leading real estate. Wildcat Partner Holdings, LP is a separately identified related investment partnership rather than a new firm-level fundraising event. No verified external fund close or firm cash raise was found in the reviewed primary materials. Published transaction-size criteria and securities holdings are not treated as capital raised. Wildcat Capital Management is distinct from Wildcat Venture Partners and Wildcat Discovery Technologies.

AME Cloud Ventures is Jerry Yang’s technology investment platform, backing seed through later-stage businesses in data, machine intelligence, cloud infrastructure and hardware. Its own public directory names Jeff Chung, Wretch Chien, Jerry Yang, Nick Adams and Cathy Luu. The directory explicitly says Adams stepped back from new investments in 2020 while remaining a venture partner; older outside board affiliations are not treated as confirmed current appointments. Relevant published investment examples include Freenome, Synthego, Rigetti Quantum Computing, Nervana Systems, Capella Space and Vicarious Surgical. SEC issuer agreements establish distinct affiliated investment vehicles AME Cloud Ventures Fund I LLC, AME 2019 Fund LP and AME Cloud Ventures LP, alongside AME Cloud Ventures LLC. AME 2019 GP LLC and AME Cloud Holdings LLC are identified as general partners of the corresponding partnerships. These legal vehicles are recorded under the retained institutional platform without assuming that one LLC is the exclusive manager or that all transactions use the same subscriber. Fund closed amounts and closing dates are not publicly established by the reviewed documents. Portfolio-company fundraising, issuer holdings and signatures do not establish a new manager fund close or a particular investee cash allocation. Gregory R. Hardester is recorded only as a historical manager/authorized signatory established by 2021 agreements, not as a confirmed current investment partner. Existing investment records remain preserved.

Emergence Capital is a venture capital firm focused exclusively on business-to-business software and the founders changing how work gets done. It invests from early stages in AI-native services, enterprise applications and technology infrastructure, providing concentrated long-term support in hiring, go-to-market execution and company strategy through its investment and operating teams.

Four Rivers Group is a San Francisco-based technology venture capital firm managing seed, expansion-stage and secondary investment strategies. Its seed funds provide first institutional capital to young companies; expansion funds finance growing market leaders; secondary funds provide partial liquidity to founders, management teams and existing investors. The firm backs global software and technology businesses, with published seed expertise in cloud infrastructure and developer services and portfolio exposure to AI, cybersecurity, enterprise software and technology-enabled healthcare. Its published human roster includes managing partners, strategic limited partners and an external advisory board; those categories have distinct responsibilities.

Industry Ventures is a US venture-capital and technology-investment platform founded in 2000, with its own legal disclosures identifying Industry Ventures, LLC in San Francisco. Its strategies combine emerging-manager primary commitments, LP secondaries, direct growth investments, late-stage company secondaries and technology buyouts. Goldman Sachs completed its acquisition effective January 2, 2026, and the team joined Goldman Sachs’ External Investing Group. This ownership change is qualified in the retained manager profile; historical portfolio buyers, legal fund vehicles and transactions are not replaced with parent-company cash records. The current own directory publishes 40 investment, capital-formation, legal, finance and operations people, including Goldman Sachs staff assigned to this platform. A separate retained firm, 33:Industry Ventures at 33industry.com, is unrelated to the demonstrated US manager identity and is preserved separately. Relevant investments include AI and software businesses, healthcare and cognitive-care company Isaac Health; primary investor announcements and portfolio records distinguish direct ownership from exposure through managed LP interests or secondary purchases. Twenty sourced fund-vehicle records preserve announced final closes and disclosed commitment sizes from 2009 through 2024. Figures given only for combined vehicles, amounts exceeding a stated lower bound, or totals including affiliated entities remain qualified in evidence with individual amount fields blank where the exact allocation is unpublished. Its advertised $8B-plus AUM, strategy totals and acquisition consideration are not new fund cash closes. The current genuine publisher logo reflects its Goldman Sachs affiliation. Existing 17 investment payloads and protected legacy references remain unchanged.